The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man

Status unconfirmed · Phase 1 · Has a placebo group

Conditions studied: Insulin Resistance

In brief

To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.

Key facts

Study ID

NCT02518932

Run by

Elahi, Dariush, PhD

People needed

20

Starts

2015-03-01

Expected to finish

2016-03-01

Last updated by the study team

2015-08-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• BMI 18.5-25;
• 33-38

You may not qualify if…

• T2D
• T1D
• Hypoglycemic agents

Where it is running

• ICON PLC — San Antonio, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.